Journal of Plant Biotechnology

The Korean Society of Plant Biotechnology (한국식물생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Development of adjuvant for effective oral vaccine application

경구백신의 효율적인 적용을 위한 면역 보조제 개발

  • Kim, Sae-Hae (Division of Biological Sciences, Chonbuk National University) ;
  • Seo, Ki-Weon (Division of Biological Sciences, Chonbuk National University) ;
  • Kim, Ju (Jeonju Biomaterials Institute) ;
  • Jang, Yong-Suk (Division of Biological Sciences, Chonbuk National University)
  • 김새해 (전북대학교 생물과학부) ;
  • 서기원 (전북대학교 생물과학부) ;
  • 김주 (전주생물소재연구소) ;
  • 장용석 (전북대학교 생물과학부)
  • Received : 2010.08.07
  • Accepted : 2010.08.20
  • Published : 2010.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Vaccine is one of the best known and most successful applications of immunological theory to human health and it protects human life through inducing the immune response in systemic compartment. However, when we consider the fact that mucosal epithelium is exposed to diverse foreign materials including viruses, bacteria, and food antigens and protects body from entry of unwanted materials using layer of tightly joined epithelial cells, establishing the immunological barrier on the lining of mucosal surfaces is believed to be an effective strategy to protect body from unwanted antigens. Unfortunately, however, oral mucosal site, which is considered as the best target to induce mucosal immune response due to application convenience, is prone to induce immune tolerance rather than immune stimulation. Since intestinal epithelium is tightly organized, a prerequisite for successful mucosal vaccination is delivery of antigen to mucosal immune induction site including a complex system of highly specialized cells such as M cells. Consequently, development of efficient mucosal adjuvant capable of introducing antigens to mucosal immune induction site and overcome oral tolerance is an important subject in oral vaccine development. In this review, various approaches on the development of oral mucosal adjuvants being suggested for effective oral mucosal immune induction.

Keywords

References

  1. Abreu MT (2010) Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 10:131-144 https://doi.org/10.1038/nri2707
  2. Bevan MJ (2004) Helping the CD8 (+) T-cell response. Nat Rev Immunol 4:595-602 https://doi.org/10.1038/nri1413
  3. Blanco HM, Lacoste MG, Elicabe RJ, Di Genaro MS (2008) IgA response by oral infection with an attenuated Yersinia enterocolitica mutant: implications for its use as oral carrier vaccine. Vaccine 26:6497-6502 https://doi.org/10.1016/j.vaccine.2008.09.046
  4. Brandtzaeg P (2009) Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol 70:505-515 https://doi.org/10.1111/j.1365-3083.2009.02319.x
  5. Brandtzaeg P, Johansen FE (2005) Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol Rev 206:32-63 https://doi.org/10.1111/j.0105-2896.2005.00283.x
  6. Brandtzaeg P, Kiyono H, Pabst R, Russell MW (2008) Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol 1:31-37 https://doi.org/10.1038/mi.2007.9
  7. Brayden DJ, Jepson MA, Baird AW (2005) Keynote review: intestinal Peyer’s patch M cells and oral vaccine targeting. Drug Discov Today 10:1145-1157 https://doi.org/10.1016/S1359-6446(05)03536-1
  8. Cerutti A (2008) The regulation of IgA class switching. Nat Rev Immunol 8:421-434 https://doi.org/10.1038/nri2322
  9. Cerutti A, Rescigno M (2008) The biology of intestinal immunoglobulin A responses. Immunity 28:740-750 https://doi.org/10.1016/j.immuni.2008.05.001
  10. Chadwick S, Kriegel C, Amiji M (2010) Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev 62:394-407 https://doi.org/10.1016/j.addr.2009.11.012
  11. Chen D, Endres RL, Erickson CA, Maa YF, Payne LG (2002) Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity. Vaccine 20:2671-2679 https://doi.org/10.1016/S0264-410X(02)00215-3
  12. Chwalek M, Lalun N, Bobichon H, Ple K, Voutquenne-Nazabadioko L (2006) Structure-activity relationships of some hederagenin diglycosides: haemolysis, cytotoxicity and apoptosis induction. Biochim Biophys Acta 1760:1418-1427 https://doi.org/10.1016/j.bbagen.2006.05.004
  13. Clark MA, Jepson MA (2003) Intestinal M cells and their role in bacterial infection. Int J Med Microbiol 293:17-39 https://doi.org/10.1078/1438-4221-00242
  14. Duc M, Johansen FE, Corthesy B. (2010) Antigen binding to secretory immunoglobulin A results in decreased sensitivity to intestinal proteases and increased binding to cellular Fc receptors. J Biol Chem 285:953-960 https://doi.org/10.1074/jbc.M109.059220
  15. Fagarasan S, Kawamoto S, Kanagawa O, Suzuki K (2010) Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis. Annu Rev Immunol 28:243-273 https://doi.org/10.1146/annurev-immunol-030409-101314
  16. Fievez V, Plapied L, des Rieux A, Pourcelle V, Freichels H, Wascotte V, Vanderhaeghen ML, Jerome C, Vanderplasschen A, Marchand-Brynaert J, Schneider YJ, Preat V (2009) Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur J Pharm Biopharm 73:16-24 https://doi.org/10.1016/j.ejpb.2009.04.009
  17. Gebert A, Rothkotter HJ, Pabst R (1996) M cells in Peyer’s patches of the intestine. Int Rev Cytol 167:91-159 https://doi.org/10.1016/S0074-7696(08)61346-7
  18. Hase K, Kawano K, Nochi T, Pontes GS, Fukuda S, Ebisawa M, Kadokura K, Tobe T, Fujimura Y, Kawano S, Yabashi A, Waguri S, Nakato G, Kimura S, Murakami T, Iimura M, Hamura K, Fukuoka S, Lowe AW, Itoh K, Kiyono H, Ohno H (2009) Uptake through glycoprotein 2 of FimH (+) bacteria by M cells initiates mucosal immune response. Nature 462:226-230 https://doi.org/10.1038/nature08529
  19. Holmgren J, Czerkinsky C (2005) Mucosal immunity and vaccines. Nat Med 11:S45-53 https://doi.org/10.1038/nm1213
  20. Iwasaki A (2007) Mucosal dendritic cells. Annu Rev Immunol 25:381-418 https://doi.org/10.1146/annurev.immunol.25.022106.141634
  21. Jepson MA, Clark MA, Hirst BH (2004) M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery. Adv Drug Deliv Rev 56:511-525 https://doi.org/10.1016/j.addr.2003.10.018
  22. Keljo DJ, Hamilton JR (1983) Quantitative determination of macromolecular transport rate across intestinal Peyer’s patches. Am J Physiol 244:G637-644
  23. Kendall MA (2010) Needle-free vaccine injection. Handb Exp Pharmacol 193-219
  24. Kiyono H, Fukuyama S (2004) NALT- versus Peyer’s-patchmediated mucosal immunity. Nat Rev Immunol 4:699-710 https://doi.org/10.1038/nri1439
  25. Knoop KA, Kumar N, Butler BR, Sakthivel SK, Taylor RT, Nochi T, Akiba H, Yagita H, Kiyono H, Williams IR (2009) RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol 183:5738-5747 https://doi.org/10.4049/jimmunol.0901563
  26. Kopecky-Bromberg SA, Fraser KA, Pica N, Carnero E, Moran TM, Franck RW, Tsuji M, Palese P (2009) Alpha-Cgalactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine 27:3766-3774 https://doi.org/10.1016/j.vaccine.2009.03.090
  27. Kuolee R, Chen W (2008) M cell-targeted delivery of vaccines and therapeutics. Expert Opin Drug Deliv 5:693-702 https://doi.org/10.1517/17425247.5.6.693
  28. Mach J, Hshieh T, Hsieh D, Grubbs N, Chervonsky A (2005) Development of intestinal M cells. Immunol Rev 206:177-189 https://doi.org/10.1111/j.0105-2896.2005.00281.x
  29. Man AL, Lodi F, Bertelli E, Regoli M, Pin C, Mulholland F, Satoskar AR, Taussig MJ, Nicoletti C (2008) Macrophage migration inhibitory factor plays a role in the regulation of microfold (M) cell-mediated transport in the gut. J Immunol 181:5673-5680 https://doi.org/10.4049/jimmunol.181.8.5673
  30. Marra A, Isberg RR (1997) Invasin-dependent and invasinindependent pathways for translocation of Yersinia pseudotuberculosis across the Peyer’s patch intestinal epithelium. Infect Immun 65:3412-3421
  31. McGhee JR, Kunisawa J, Kiyono H (2007) Gut lymphocyte migration: we are halfway ‘home’. Trends Immunol 28:150-153 https://doi.org/10.1016/j.it.2007.02.001
  32. Mestecky J, Nguyen H, Czerkinsky C, Kiyono H (2008) Oral immunization: an update. Curr Opin Gastroenterol 24:713-719 https://doi.org/10.1097/MOG.0b013e32830d58be
  33. Mishra N, Goyal AK, Tiwari S, Paliwal R, Paliwal SR, Vaidya B, Mangal S, Gupta M, Dube D, Mehta A, Vyas SP (2010) Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers. Expert Opin Ther Pat 20:661-679 https://doi.org/10.1517/13543771003730425
  34. Misumi S, Masuyama M, Takamune N, Nakayama D, Mitsumata R, Matsumoto H, Urata N, Takahashi Y, Muneoka A, Sukamoto T, Fukuzaki K, Shoji S (2009) Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer. J Immunol 182:6061-6070 https://doi.org/10.4049/jimmunol.0802928
  35. Nochi T, Yuki Y, Katakai Y, Shibata H, Tokuhara D, Mejima M, Kurokawa S, Takahashi Y, Nakanishi U, Ono F, Mimuro H, Sasakawa C, Takaiwa F, Terao K, Kiyono H (2009) A rice-based oral cholera vaccine induces macaque- specific systemic neutralizing antibodies but does not influence pre-existing intestinal immunity. J Immunol 183:6538-6544 https://doi.org/10.4049/jimmunol.0901480
  36. Nochi T, Yuki Y, Matsumura A, Mejima M, Terahara K, Kim DY, Fukuyama S, Iwatsuki-Horimoto K, Kawaoka Y, Kohda T, Kozaki S, Igarashi O, Kiyono H (2007) A novel M cellspecific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J Exp Med 204:2789-2796 https://doi.org/10.1084/jem.20070607
  37. Parrott DM (1976) The gut as a lymphoid organ. Clin Gastroenterol 5:211-228 https://doi.org/10.1097/00004836-198306000-00003
  38. Plotkin SA (2005) Vaccines: past, present and future. Nat Med 11:S5-11
  39. Ragnarsson EG, Schoultz I, Gullberg E, Carlsson AH, Tafazoli F, Lerm M, Magnusson KE, Soderholm JD, Artursson P (2008) Yersinia pseudotuberculosis induces transcytosis of nanoparticles across human intestinal villus epithelium via invasindependent macropinocytosis. Lab Invest 88:1215-1226 https://doi.org/10.1038/labinvest.2008.86
  40. Reed SG, Bertholet S, Coler RN, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30:23-32 https://doi.org/10.1016/j.it.2008.09.006
  41. Rynda A, Maddaloni M, Mierzejewska D, Ochoa-Reparaz J, Maslanka T, Crist K, Riccardi C, Barszczewska B, Fujihashi K, McGhee JR, Pascual DW (2008) Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma 1. J Immunol 180:5187-5200 https://doi.org/10.4049/jimmunol.180.8.5187
  42. Siebers A, Finlay BB (1996) M cells and the pathogenesis of mucosal and systemic infections. Trends Microbiol 4:22-29 https://doi.org/10.1016/0966-842X(96)81501-0
  43. Slutter B, Plapied L, Fievez V, Sande MA, des Rieux A, Schneider YJ, Van Riet E, Jiskoot W, Preat V (2009) Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release 138:113-121 https://doi.org/10.1016/j.jconrel.2009.05.011
  44. Sun JB, Czerkinsky C, Holmgren J (2010) Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand J Immunol 71:1-11 https://doi.org/10.1111/j.1365-3083.2009.02321.x
  45. Takahashi I, Nochi T, Yuki Y, Kiyono H (2009) New horizon of mucosal immunity and vaccines. Curr Opin Immunol 21:352-258 https://doi.org/10.1016/j.coi.2009.04.002
  46. Tokuhara D, Yuki Y, Nochi T, Kodama T, Mejima M, Kurokawa S, Takahashi Y, Nanno M, Nakanishi U, Takaiwa F, Honda T, Kiyono H (2010) Secretory IgA- mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine. Proc Natl Acad Sci USA 107:8794-8799 https://doi.org/10.1073/pnas.0914121107
  47. Tomasi Jr TB, Tan EM, Solomon A, Prendergast RA (1965) Characteristics of an immune system common to certain external secretions. J Exp Med 121:101-124 https://doi.org/10.1084/jem.121.1.101
  48. Tsuji NM, Kosaka A (2008) Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol 29:532-540 https://doi.org/10.1016/j.it.2008.09.002
  49. Tyrer PC, Ruth Foxwell A, Kyd JM, Otczyk DC, Cripps AW (2007) Receptor mediated targeting of M-cells. Vaccine 25:3204-3209 https://doi.org/10.1016/j.vaccine.2007.01.028
  50. Wershil BK, Furuta GT (2008) 4. Gastrointestinal mucosal immunity. J Allergy Clin Immunol 121:S380-383 https://doi.org/10.1016/j.jaci.2007.10.023
  51. Wu Y, Wang X, Csencsits KL, Haddad A, Walters N, Pascual DW (2001) M cell-targeted DNA vaccination. Proc Natl Acad Sci USA 98:9318-9323 https://doi.org/10.1073/pnas.161204098